BR12

Temozolomide versus PCV chemotherapy in the treatment of recurrent malignant glioma

Which drugs work best against brain tumours which come back (recur)?

What is this study about?

This trial aims to find out which of two drug treatments can best help people with a particular type of brain tumour which has become active again after treatment with radiotherapy.

The tumour is called high grade glioma. The usual treatment at this stage is a combination of three drugs called PCV, but something better is needed. Another drug called temozolomide (Temodol) looks promising, but it has never been directly compared with PCV in this patient group. The trial will assess which treatment is more effective, and which is more acceptable to patients in terms of side-effects. As part of this trial, there are two different doses of temozolomide patients could receive. This will help us see if giving people a lower dose over a longer period will work as well as a higher dose over a shorter period, but with fewer side effects. Patients will be randomly selected by computer to one of the three treatments available.

Type of study

Randomised trial

Contact details

BR12@ctu.mrc.ac.uk

Who is funding the study?

The charity Cancer Research UK.

When is it taking place?

The trial finished recruiting patients in January 2008.

Where is it taking place?

Hospitals throughout the UK.

Who is included?

People with high grade glioma which has come back (recurred)